Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery
ChiCTR2600126491Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of amisulpride in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Complete remission (CR) within 24 hours after surgery. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2600126491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126491.